Alfacalcidol in the therapy of renal bone disease

International Journal of Clinical Pharmacology and Therapeutics

Volumn 39, Issue 12, 2001, Pages 546-550

  Ritzerfeld, M ^a   Klasser, M ^a   Mann, H ^a  

^a Dialysezentrum   (Germany)

Author keywords

Alfacal cidol; Hypercalcemia; Parathyroidism; Renal osteopathy; Secondary hyper; Vitamin D3 metabolites

Indexed keywords

ALFACALCIDOL; ALKALINE PHOSPHATASE; ALUMINUM; BONDIOL; CALCITRIOL; CALCIUM; COLECALCIFEROL DERIVATIVE; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL OBSERVATION; CONSTIPATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; HEARTBURN; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPOCALCEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROLOGY; PARATHYROID ADENOMA; PHOSPHATE BLOOD LEVEL; POSTMARKETING SURVEILLANCE; PRURITUS; RENAL OSTEODYSTROPHY; SECONDARY HYPERPARATHYROIDISM; URINARY EXCRETION; VERTIGO;

EID: 0035199755     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP39546     Document Type: Article

References (43)

1. The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques
2. Studies on the mechanism on fibrate inhibited expression of plasminogen activator inhibitor-1 in cultured hepatocytes from cynomolgus monkey
3. Effect of atorvastatin versus simvastatin on lipid profile and plasma fibrinogen in patients with hypercholesterolemia
4. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation
5. Very low-density lipoprotein-mediated signal transduction and plasminogen activator inhibitor type 1 in cultured HepG2 cells
6. Gemfibrozil treatment of combined hyper-lipoproteinemia
7. Activation of proliferator-activated receptors α and y induces apoptosis of human monocyte-derived macrophages
8. Inflammation-coagulation network: Are serine protease receptors the knot?
9. Down-regulation of cytochrome P420 family members and positive acute-phase response gene expression by peroxisome proliferator chemicals
10. Fibrinolytic activation markers predict myocardial infarction in the elderly
11. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia
12. Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidaemia
13. Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients
14. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinemia
15. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance
16. Acute coronary syndromes biology
17. Effects of statins on triglyceride metabolism
18. Lysophospholipids and eicosanoids in biology and pathophysiology
19. Inhibition of matrix metalloproteinases: Therapeutic applications
20. Interactions between endothelial secretogogues
21. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor
22. Fibrinolytic function and coronary risk
23. Fibrinogen and risk of cardiovascular disease: The Framingham Study
24. Collagen platelet interaction Gly-Pro-Hyp is uniquely specific for platelet Gp VI and mediates platelet activation by collagen
25. Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients
26. Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes - Role of the peroxisome proliferator-activated receptor-α
27. Fasting insulin and apolipoprotein B levels and law - density lipoprotein particle size as a risk factor for ischemic heart disease
28. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease
29. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors
30. The adipocyte and hemostatic balance in obesity. Studies of PAI-1
31. PPAR alpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells
32. Effects of lipids and lipoproteins on thrombosis and rheology
33. Role of the peroxisome proliferator activated receptor (PPAR) in mediating effects of fibrates and fatty acids on gene expression
34. The fibrates clinical practice: Focus on micronized fenofibrate
35. Mechanism of action of fibrates on lipid and lipoprotein metabolism
36. Fibrinogen, viscosity, and the 10-year incidence of ischemic heart disease
37. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarcion in both men and women: Evidence for fibrinolytic system as an independent primary risk factor
38. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease
39. Infections, inflammation, and infarction: Does acute endothelial dysfunction provide a link?
40. Atherosclerotic plaque rupture-pathologic basis of plaque stability and instability
41. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in Stockholm Heart Epidemiology Program (SHEEP) study
42. Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged men and women
43. Beneficial effect of gemfibrozil on the chemical composition and oxidative susceptibility of low-density lipoprotein: A randomized, double-blind, placebo-controlled study